The Cuban biopharmaceutical industry has incorporated into its 2025–2035 strategy the development of 19 biosimilar and generic products, mainly focused on areas such as oncology, autoimmune diseases, hematology and diabetes mellitus.

These drugs, already approved by regulatory authorities, share structure, efficacy and safety with reference biological products, but can be offered at lower costs, according to information from Prensa Latina, a partner of the TV BRICS network.

A pharmaceutical business group currently has several biosimilars in use, including products for chronic kidney failure and for the treatment of cancer, and others intended for various infectious, oncological and cardiovascular pathologies.

The main objective of this strategy is to facilitate the incorporation of new medicines into the National Health System and expand the catalog of Cuba's exportable products.

The initiative was presented by specialists during a meeting between President Miguel Díaz-Canel and scientists, in which key priorities for the development of the country's health system were analyzed.